China News Service, June 21st (Chen Jing and Xu Lanqing) In recent years, the incidence of cervical cancer in China has shown an upward trend and a younger trend. To formulate prevention and control strategies for cervical cancer, we must start with primary prevention and promote vaccination of women of the right age, especially girls Vaccines have become the common voice of experts.

　　The reporter learned during several days of visits that at present, many medical institutions are out of stock for imported HPV vaccines, and the waiting time for appointments is long.

In an interview with reporters on the 21st, Yang Fang, an expert in the special needs vaccination clinic of Shanghai Renai Hospital, said that the current domestic bivalent HPV vaccine supply is relatively sufficient, and women of the right age are vaccinated and protected early.

　　It is reported that more than 90% of cervical cancers are caused by persistent infection with the high-risk human papillomavirus (HPV) virus, and the advent of the HPV vaccine makes cervical cancer the only cancer in the world that can be prevented by vaccines.

　　According to the number of preventable HPV virus subtypes, HPV vaccines currently on the market are mainly divided into divalent, quadrivalent and ninth valent, of which the bivalent is divided into domestic and imported.

The imported bivalent HPV vaccine is provided by GlaxoSmithKline; the imported quadrivalent and 9-valent HPV vaccine is provided by Merck.

During the interview, the reporter found that the four-valent and nine-valent vaccines that can provide more protection are more popular with young people, and they are more likely to face shortages or tight supplies.

　　It is understood that due to the complicated production process of the vaccine, the production cycle is long.

The HPV vaccine production cycle takes four years, and companies need to make a four or five-year plan to meet demand.

With the liberalization of the Chinese market, the improvement of national health awareness and the popularization of medical knowledge, HPV vaccines are generally out of stock.

　　On December 31, 2019, the National Food and Drug Administration approved the domestic human papillomavirus (HPV) vaccine to be marketed, which is applicable to women aged 9-45 years old.

Clinical trial results show that the relevant domestic bivalent HPV vaccines have a protection rate of 100% against HPV16 and HPV18-related precancerous lesions, and a protection rate of 97.7% against persistent infections of HPV16 and HPV18. The relevant key indicators are not inferior to imported bivalent and IV. Valence vaccine.

At the same time, domestically produced bivalent HPV vaccines also have price advantages.

　　Yang Fang said that, in fact, whether imported or domestically produced, HPV vaccines are vaccinated early and protected.

(Finish)